Generic Name and Formulations:
Nisoldipine 8.5mg, 17mg*, 34mg; ext-rel tabs; *contains tartrazine.
Covis Pharmaceuticals, Inc.
Indications for SULAR:
Swallow whole. Take on an empty stomach (1hr before or 2hrs after a meal). Initially 17mg once daily; may increase by 8.5mg per week or longer intervals. Usual maintenance: 17–34mg once daily; max 34mg/day. Hepatic impairment or elderly (>65yrs): Initially 8.5mg once daily.
Coronary artery disease. Heart failure or compromised ventricular function (esp. with a beta-blocker). Monitor BP closely during initiation and titration. Severe hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Calcium channel blocker (CCB) (dihydropyridine).
Avoid concomitant CYP3A4 inhibitors or inducers, grapefruit juice. High-fat meals increase peak drug concentrations. Antagonized by phenytoin (avoid; consider alternatives). May be potentiated by cimetidine.
Peripheral edema, headache, dizziness, pharyngitis, vasodilation, sinusitis, palpitations, chest pain, nausea, rash; increased angina, MI (rare), hypotension.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D